IL-4 R alpha

IL-4 R alpha 詳細

英語名Interleukin-4 receptor subunit alpha市販薬剤の数2
治験薬の数24ターゲットの別称Interleukin 4 Receptor,IL-4 Receptor Subunit Alpha,Interleukin 13 Receptor,IL4RA,Interleukin-4 Receptor Subunit Alpha,Interleukin-4 Receptor Alpha Chain,IL4R Nirs Variant 1,IL-4R Subunit Alpha,CD124 Antigen,Interleukin-4 Receptor alpha Subunit,IL4Rα,IL-4R-alpha,Soluble IL-4 receptor subunit alpha,582J2.1,Soluble IL-4R-alpha,IL-4-binding protein,IL-4RA,IL4-BP,sIL4Ralpha/prot,CD124,IL4R
研究&開発段階Approved
英語名Interleukin-4 receptor subunit alpha
ターゲットの別称Interleukin 4 Receptor,IL-4 Receptor Subunit Alpha,Interleukin 13 Receptor,IL4RA,Interleukin-4 Receptor Subunit Alpha,Interleukin-4 Receptor Alpha Chain,IL4R Nirs Variant 1,IL-4R Subunit Alpha,CD124 Antigen,Interleukin-4 Receptor alpha Subunit,IL4Rα,IL-4R-alpha,Soluble IL-4 receptor subunit alpha,582J2.1,Soluble IL-4R-alpha,IL-4-binding protein,IL-4RA,IL4-BP,sIL4Ralpha/prot,CD124,IL4R
市販薬剤の数2
治験薬の数24
研究&開発段階Approved

IL-4 R alphaバックグランド

IL-4 is a pleiotropic cytokine produced by activated Th2 cells and mast cells, and plays a pivotal role in immune responses. The effects of IL-4 are mediated after binding to high affinity receptor complexes present on hematopoietic as well as non-hematopoietic cells. Hematopoietic cellular responses to IL-4 are mediated by a high affinity receptor complex comprised of the 140 kDa IL4Rα (CD124)subunit and the 70 kDa common cytokine γc chain (CD132). Interleukin 4 Receptor (IL4R) also known as CD124, IL4Rα and BSF receptor, is a type I cytokine receptor produced by activated Th2 cells and mast cells, and plays an important role in Th2-­biased immune responses, alternative macrophage activation, mucosal immunity, allergic inflammation, tumor progression, and atherogenesis. A soluble form of the encoded IL4R protein can be produced by an alternate splice variant or by proteolysis of the membrane-bound protein, and this soluble form can inhibit IL4-mediated cell proliferation and IL5 upregulation by T-cells. IL4R can alternatively associate with IL­13Ra1 to form the type II receptor which is responsive to both IL­4 and IL­13. Interleukin-4 receptor has been shown to interact with SHC1.

IL-4 R alpha分子の別称

IL4R,CD124,IL4RA

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
OturkibartHDM3016; QX-005N; HDM-3016Phase 3 ClinicalQyuns Therapeutics Co LtdAsthma; Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Prurigo; Pulmonary Disease, Chronic Obstructive; Sinusitis
詳細
Dupilumab biosimilar (Jingxing Pharmaceutical)GS101; GS-101; GS-101 (Jingxing Pharmaceutical)Phase 3 ClinicalJiangsu Jingxing Pharmaceutical Technology Co LtdDermatitis, Atopic
詳細
Dupilumab biosimilar (Qilu Pharma)QL2108; QL-2108Phase 3 ClinicalQilu Pharmaceutical Co LtdAsthma; Dermatitis, Atopic; Prurigo
詳細
siLR4AsiLR4APhase 3 ClinicalNational Skin Centre, SingaporeKeloid; Wounds and Injuries
詳細
TQH2722TQC2722; TQC-2722; TQH 2722; TQH-2722; TQH2722; BSI-045APhase 3 ClinicalBiosion Inc, Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupDermatitis, Atopic; Inflammation; Nasal Polyps; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Sinusitis
詳細
SHR-1819SHR-1819Phase 3 ClinicalShanghai Hengrui Pharmaceutical Co LtdAsthma; Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Prurigo; Prurigo Nodularis; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Sinusitis
詳細
JNJ-5939JNJ-5939; NM-26; NM26-2198; JNJ-95475939Phase 2 ClinicalNumab Therapeutics AgDermatitis, Atopic; Inflammation
詳細
AK-139AK139; AK-139Phase 2 ClinicalKangfang Biotechnology (Cayman) Co LtdAsthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Hypersensitivity; Prurigo Nodularis; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal
詳細
IBI-3002IBI3002; IBI-3002Phase 2 ClinicalAsthma; Dermatitis, Atopic
詳細
SHR-4597SHR-4597; SHR4597Phase 2 ClinicalGuangdong Hengrui Pharmaceutical Co LtdAsthma
詳細
RC-1416RC14/16; RC-1416Phase 2 ClinicalNanjing RegeneCore Biotech Co LtdAsthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive
詳細
BA-2101BA-2101; BA2101; PR-103; PR103Phase 2 ClinicalShandong Boan Biotechnology Co LtdAsthma; Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Prurigo; Pruritus; Pulmonary Disease, Chronic Obstructive; Sinusitis; Urticaria
詳細
Sorafenib Tosylate/ComekibartMG-D-1609Phase 2 ClinicalMetagone Biotech IncSolid tumours
詳細
LQ-036LQ-036Phase 2 ClinicalShanghai Novamab Biopharmaceuticals Co LtdAsthma; Pulmonary Disease, Chronic Obstructive
詳細
Dupixent biosimilar (Chong Kun Dang Pharmaceutical)CKD-706Phase 1 ClinicalChong Kun Dang Pharmaceutical CorpDermatitis, Atopic
詳細
Dupilumab biosimilar (China Resources Biopharma)Phase 1 ClinicalChina Resources Biopharmaceutical Co LtdDermatitis, Atopic
詳細
Dupilumab biosimilar (Jiangsu Jingxing Pharma)Phase 1 ClinicalJiangsu Jingxing Pharmaceutical Technology Co LtdDermatitis, Atopic
詳細
Dupilumab biosimilar (Chengdu Kanghong)KH-816; KH816Phase 1 ClinicalChengdu Kanghong Biotechnologies Co LtdDermatitis, Atopic
詳細
BR-2060BR-2060; BR2060Phase 1 ClinicalZhejiang BioRay Biopharmaceuticals Co LtdAutoimmune Diseases; Dermatitis, Atopic
詳細
Dupilumab biosimilar (Jushi Biopharma)Phase 1 ClinicalJushi Biopharmaceutical Co LtdDermatitis, Atopic
詳細
BBT-001BBT001; BBT-001Phase 1 ClinicalBambusa Therapeutics IncDermatitis, Atopic
詳細
Dupilumab biosimilar (Bio-Thera Solutions)BAT2406; BAT-2406Phase 1 ClinicalBio-Thera Solutions LtdAsthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Nasal Polyps; Prurigo Nodularis; Sinusitis
詳細
APG-808APG808; PR-001; PR001; APG-808Phase 1 ClinicalApogee Therapeutics Inc, Paragon Therapeutics IncPulmonary Disease, Chronic Obstructive
詳細
HY-1770HY-1770; HT-17; HT17; YF02; HT25; GH02; HY1770Phase 1 ClinicalSuzhou Pharmavan Co LtdDermatitis, Atopic; Plaque psoriasis
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
StapokibartCM-310ApprovedKeymed Biosciences Co Ltd康悦达, KangyuedaMainland ChinaDermatitis, AtopicChengdu Kangnuoxing Biopharma Inc2024-09-10Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Conjunctivitis, Allergic; Dermatitis, Atopic; Nasal Polyps; Pemphigoid, Bullous; Prurigo; Prurigo Nodularis; Pruritus; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Sinusitis; Solid tumours
詳細
DupilumabREGN-668; SAR-231893ApprovedRegeneron Pharmaceuticals Inc, SanofiDupixent, 达必妥United StatesDermatitis, AtopicRegeneron Pharmaceuticals Inc2017-03-28Allergic Fungal Rhinosinusitis; Alopecia Areata; Angioedema; Aspergillosis, Allergic Bronchopulmonary; Asthma; Asthma, Aspirin-Induced; Chronic Urticaria; Colitis, Ulcerative; Conjunctivitis, Allergic; Coronavirus Disease 2019 (COVID-19); Dermatitis; Dermatitis, Atopic; Eczema; Eosinophilic Esophagitis; Eosinophilic gastroenteritis (EG); Genetic Diseases, Inborn; Hypereosinophilic Syndrome; Hypersensitivity; Hypersensitivity, Immediate; Keloid; Keratoconjunctivitis; Lichenoid Eruptions; Milk Hypersensitivity; Nasal Polyps; Nephrotic Syndrome; Neurodermatitis; Paranasal Sinus Diseases; Peanut Hypersensitivity; Pemphigoid, Bullous; Prostatic Neoplasms; Prurigo; Prurigo Nodularis; Pruritus; Pulmonary Disease, Chronic Obstructive; Respiration Disorders; Respiratory Sounds; Respiratory Tract Diseases; Rhinitis, Allergic; Scleroderma, Localized; Sinusitis; Skin Diseases; Skin Diseases, Eczematous; Sleep Apnea Syndromes; Urticaria
詳細

レビュー

  • 詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • レビュー
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8